Print

Purpose

The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.

Condition

Eligibility

Eligible Ages
Between 12 Years and 75 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of HS for at least 6 months before screening visit. - Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct anatomical areas at screening and Day 1 visits. - Total estimated treatment BSA > 20% at screening and baseline. - Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period. - Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol. - Further inclusion criteria apply.

Exclusion Criteria

  • Current or history of skin condition(s) other than HS that might confound the evaluation of HS; clinically uncontrolled cardiovascular disease; thrombosis; certain cancers; certain infections; severe anemia, thrombocytopenia, or neutropenia; other medical conditions at the discretion of the investigator. - Laboratory values outside of the protocol-defined ranges. - Further exclusion criteria apply.

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Ruxolitinib 1.5 % Cream 		Participants received ruxolitinib 1.5% cream, applied topically to the affected area as defined in the protocol.
  • Drug: Ruxolitinib Cream
    Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

Recruiting Locations

Saguaro Dermatology
Phoenix, Arizona 85008

First Oc Dermatology
Fountain Valley, California 92708

Amicis Research Center Valencia
Northridge, California 91324

Clinical Trials Research Institute
Thousand Oaks, California 91320

Clarity Dermatology
Castle Rock, Colorado 80109

International Clinical Research Tennessee Llc
Sanford, Florida 32771

Lenus Research Medical Group, Llc
Sweetwater, Florida 33172

Trueblue Clinical Research
Tampa, Florida 33609

Lane Dermatology and Dermatologic Surgery
Columbus, Georgia 31904

Options Research Group, Llc
West Lafayette, Indiana 47906

Equity Medical, Llc
Bowling Green, Kentucky 42104

Delricht Research
Baton Rouge, Louisiana 70809

Revival Research Institute, Llc Troy
Troy, Michigan 48084

Red River Research Partners
Bolivar, Missouri 65613

Dr Bobby Buka, Md Greenwich Village
New York, New York 10012-1354

Equity Medical, Llc
New York, New York 10019

Red River Research Partners
Fargo, North Dakota 58103

Centricity Research Columbus
Columbus, Ohio 43213

Unity Clinical Research
Oklahoma City, Oklahoma 73118

Paddington Testing Co Inc
Philadelphia, Pennsylvania 19103

More Details

Status
Recruiting
Sponsor
Incyte Corporation

Study Contact

Incyte Corporation Call Center (US)
1.855.463.3463
medinfo@incyte.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.